Targeted Delivery

Nanogenics Solutions is the exclusive licensee to the vector system (LipTide™) developed by University College London (UCL) for targeted delivery of DNA, RNA, peptides and drugs into cells. LipTide™ technology is available for sub-licensing to companies requiring targeted delivery solutions. 

Watch a video of how LipTide™ works.

  • Can be targeted to a range of tissues including lung, tumour, and vascular tissues
  • Suitable for systemic delivery, nebulisation or direct injection
  • Safe
  • Straight forward manufacturing

Discover how our technology can benefit your R&D pipeline.

The pictures below show how accurately siRNA (or any RNA) can be targeted to tumours. Unlike other lipid nanoparticles, LipTide™ does not merely end up in the sink organs as part of the clearing process.